Taken together, our results suggest that the combination of pemigatinib with radiotherapy, potentially alongside TMZ, may offer therapeutic benefit for patients with newly diagnosed GBM, particularly those with MGMT-unmethylated tumors and no detectable FGFR fusions or mutations. This evidence concerns the gene MGMT and glioblastoma.